排序方式: 共有3条查询结果,搜索用时 46 毫秒
1
1.
背景 胃黏膜保护剂对伴有症状的慢性胃炎的作用尚不明确。本研究是一项多中心、开放、随机试验,比较吉法酯和硫糖铝对伴消化不良症状的慢性胃炎的综合疗效。
方法 共有来自国内6家中心的253例证实有慢性胃炎的消化不良患者进入研究,被随机分为两组,分别接受6周的300mg/d吉法酯或3.0/d的硫糖铝治疗。研究终点是6周的内镜学改变。
结果 吉法酯对于内镜下评分和症状改善的有效率分别为72%和67%,显著高于硫糖铝组(40.1%和39.3%,P<0.001,ITT)。在组织学评价上,吉法酯和硫糖铝相比,对减轻黏膜的慢性炎症(57.7% vs 24.8%, P<0.001)和炎症活动(36.4% vs 23.1%, P<0.05)都有效。同时,吉法酯可以显著增加黏膜的前列腺素水平,降低MPO水平。黏膜糜烂的程度与症状无关,但Hp的状态影响到吉法酯的疗效。
结论 吉法酯对慢性糜烂性胃炎的黏膜炎症有显著疗效,内镜和炎症评分应该作为胃炎相关临床研究的主要评价指标。 相似文献
2.
Ellis JL Augustyniak ME Cochran ED Earl RA Garvey DS Gordon LJ Janero DR Khanapure SP Letts LG Melim TL Murty MG Schwalb DJ Shumway MJ Selig WM Trocha AM Young DV Zemtseva IS 《Inflammopharmacology》2005,12(5-6):521-534
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to treat inflammation and to provide pain relief but suffer
from a major liability concerning their propensity to cause gastric damage. As nitric oxide (NO) is known to be gastro-protective
we have synthesized a NO-donating prodrug of naproxen named NMI-1182. We evaluated two cyclo-oxygenase (COX)-inhibiting nitric
oxide donors (CINODs), NMI-1182 and AZD3582, for their ability to be gastroprotective compared to naproxen and for their anti-inflammatory
activity. NMI-1182 and AZD3582 were found to produce similar inhibition of COX activity to that produced by naproxen. Both
NMI-1182 and AZD3582 produced significantly less gastric lesions after oral administration than naproxen. All three compounds
effectively inhibited paw swelling in the rat carrageenan paw edema model. In the carrageenan air pouch model all three compounds
significantly reduced PGE2 levels in the pouch exudate but only NMI-1182 and naproxen inhibited leukocyte influx. These data demonstrate that NMI-1182
has comparable anti-inflammatory activity to naproxen but with a much reduced likelihood to cause gastric damage. 相似文献
3.
DU YQ Su T Hao JY Wang BM Chen MH Li YM Tang CW Gong YF Man XH Gao L Cai QC Li ZS 《中华医学杂志(英文版)》2012,125(16):2878-2884
Background The role of gastro-protecting agents on symptomatic chronic gastritis is unclear. This multicenter, open, randomized trial was designed to compare the comprehensive effects of gefarnate with sucralfate on erosive gastritis with dyspeptic symptoms.
Methods Totally 253 dyspepsia patients confirmed with erosive gastritis were enrolled from six centers in China. They randomly received either daily 300 mg gefarnate or 3 g sucralfate for six weeks. The primary endpoint was the effective rate of both treatments on endoscopic erosion at week six.
Results Gefarnate showed an effective rate of 72% and 67% on endoscopic score and dyspeptic symptom release, which is statistically higher than sucralfate (40.1% and 39.3%, P <0.001, intension-to-treat). For histological improvement, gefarnate showed both effective in decreasing mucosal chronic inflammation (57.7% vs. 24.8%, P <0.001, intension-to-treat) and active inflammation (36.4% vs. 23.1%, P <0.05, intension-to-treat) than the control. A significant increase of prostaglandins and decrease of myeloperoxidase in mucosa were observed in gefarnate group. Severity of erosion is non-relevant to symptoms but Helicobacter pylori (H. pylori) status does affect the outcome of therapy.
Conclusions Gefarnate demonstrates an effective outcome on the mucosal inflammation in patients with chronic erosive gastritis. Endoscopic and inflammation score should be the major indexes used in gastritis-related trials.
相似文献
1